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This international, randomized, double-blind trial (NCT01864174) compared the efficacy and
safety of metformin extended-release (XR) and immediate-release (IR) in patients with type
2 diabetes. After a 4-week placebo lead-in, pharmacotherapy-naïve adults with glycated hae-
moglobin (HbA1c) at 7.0% to 9.2% were randomized (1:1) to receive once-daily metformin XR
2000 mg or twice-daily metformin IR 1000 mg for 24 weeks. The primary endpoint was
change in HbA1c after 24 weeks. Secondary endpoints were change in fasting plasma glucose
(FPG), mean daily glucose (MDG) and patients (%) with HbA1c <7.0% after 24 weeks. Overall,
539 patients were randomized (metformin XR, N = 268; metformin IR, N = 271). Adjusted
mean changes in HbA1c, FPG, MDG and patients (%) with HbA1c <7.0% after 24 weeks were
similar for XR and IR: −0.93% vs −0.96%; −21.1 vs −20.6 mg/dL (−1.2 vs −1.1 mmol/L); −24.7
vs −27.1 mg/dL (−1.4 vs −1.5 mmol/L); and 70.9% vs 72.0%, respectively. Adverse events were
similar between groups and consistent with previous studies. Overall, metformin XR demon-
strated efficacy and safety similar to that of metformin IR over 24 weeks, with the advantage
of once-daily dosing.
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1 | INTRODUCTION
Metformin, a first-line treatment for patients with type 2 diabetes, is
available as an immediate-release (IR) formulation, typically adminis-
tered several times daily with meals, and an extended-release
(XR) formulation, administered once daily.1–6 The pharmacokinetic
properties of metformin IR are generally comparable to those of the
XR formulation.7 However, peak plasma concentrations (Cmax) for
metformin IR occur ~3 hours after a single oral 1000-mg dose (mean
Cmax [standard deviation (SD)], 1321 [234] ng/mL), whereas peak
plasma concentrations of metformin XR 2000 mg occur within 7 to
8 hours after dosing (mean Cmax [SD], 1780 [288] ng/mL).
7 Both
formulations are well tolerated and are effective in reducing glycated
haemoglobin (HbA1c) levels as compared to placebo in patients with
type 2 diabetes.8,9 Previous studies have shown greater patient
adherence10,11 and indicate improved gastrointestinal (GI) tolerability
with metformin XR compared with metformin IR.11–13
Despite widespread use of both metformin IR and XR prepara-
tions, only 2 head-to-head clinical trials comparing the safety and
efficacy of metformin IR and metformin XR have been conducted,
one in the USA and the other in China.11,12 However, both studies
included patients who had previously received metformin.11,12 The
Chinese study had an open-label design, comprising a relatively small
number of patients and comparing the 2 metformin formulations at
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1500 mg/d over 12 weeks.11 The US study was larger and of a lon-
ger duration than the Chinese study and compared metformin XR
(at different dosages) with metformin IR at a dose of 1500 mg/d. In
the US study, patients previously treated with metformin and a sul-
phonylurea were permitted.12 The aim of this trial was to evaluate
the efficacy, safety and tolerability of the same 2000 mg daily doses
of once-daily metformin XR versus twice-daily metformin IR in
pharmacotherapy-naïve patients with type 2 diabetes.
2 | METHODS
2.1 | Study design
This was an international, randomized, parallel-group, double-blind
trial (ClinicalTrials.gov identifier: NCT01864174) conducted at
148 sites (June 2013 to June 2016) in North America (USA, Canada,
Puerto Rico), Europe (Czech Republic, Germany, Hungary, Poland,
Romania, UK) and South Africa. Eligible patients entered a 4-week,
single-blind, placebo lead-in period, followed by a 24-week, random-
ized, double-blind treatment period. Patients were randomized (1:1)
to receive either once-daily metformin XR (Glucophage® XR, Bristol-
Myers Squibb) 2000 mg (with evening meals) or twice-daily metfor-
min IR (Glucophage®, Bristol-Myers Squibb) 1000 mg (every morning
and evening with meals) for 24 weeks. During the double-blind treat-
ment period, metformin XR and IR were titrated from 500 to
2000 mg/d over the first 3 weeks of treatment. Patients who were
unable to tolerate 2000 mg/d were down-titrated and re-challenge
was attempted, if possible, before week 12. The study was conducted
in accordance with Good Clinical Practice, as defined by the Interna-
tional Council for Harmonisation, and the study protocol was
approved by the Institutional Review Board/Independent Ethics
Committee at each participating institution.
2.2 | Patients
Patients (≥18 years old) who had type 2 diabetes and inadequate gly-
caemic control with diet and lifestyle advice alone (ie,
pharmacotherapy-naïve, defined as no prior pharmacotherapy for glu-
cose lowering within 90 days prior to enrolment and no more than
14 days of glucose-lowering medication) were eligible for inclusion.
Key inclusion criteria were: HbA1c, 7.0% to 9.2% at screening; body
mass index (BMI) ≤45.0 kg/m2; fasting plasma glucose (FPG)
<250 mg/dL (13.9 mmol/L); C-peptide ≥1.0 ng/mL at enrolment. Key
exclusion criteria were: history of ketoacidosis, lactic acidosis or
hyperosmolar non-ketotic coma; marked polyuria; polydipsia with
>10% weight loss during last 3 months prior to screening/enrolment;
and elevated serum creatinine levels. Patients provided written
informed consent before participating in the study, which followed
the ethical principles of the Declaration of Helsinki.
2.3 | Study assessments
The primary efficacy endpoint was mean change in HbA1c from base-
line to week 24, which was also examined by baseline HbA1c sub-
group (<8%, ≥8 to <9% and ≥9%). The secondary efficacy endpoints
were mean change in FPG and mean daily glucose (MDG) levels from
baseline to week 24 (or last observation carried forward [LOCF] for
MDG) and percentage of patients achieving a therapeutic glycaemic
response (HbA1c <7.0%) at week 24. MDG was self-monitored using
a 7-point fingerstick blood-glucose test. Mean change in body weight
and waist circumference, and mean percentage change in fasting
serum lipids from baseline to week 24 were also assessed. Safety
assessments included incidence of adverse events (AEs), clinical labo-
ratory evaluations (haematology, blood chemistry, liver function tests,
urinalysis) and vital signs. Hypoglycaemia was also assessed; all epi-
sodes consistent with the clinical definition of hypoglycemia as
assessed by the investigator were documented. Reasons for discon-
tinuation because of hypoglycaemia included, but were not limited
to, a documented fingerstick glucose value ≤54 mg/dL
(≤3.1 mmol/L).
2.4 | Statistical analyses
Given a sample size of 235 patients/group, the study would provide
90% power to demonstrate non-inferiority in change from baseline to
week 24 in mean HbA1c (assumed SD, 1.0%; non-inferiority margin,
0.3%; 2-sided α = 0.05). Assuming that approximately 10% of
patients would not have a post-baseline value, approximately
524 patients would be required for randomization.
The primary efficacy endpoint was analysed using a longitudinal
repeated-measures model, which adjusted for baseline HbA1c, treat-
ment group, time, baseline-by-time interaction and time-by-treatment
group interaction. Changes in FPG were assessed using the same
model. For MDG, changes from baseline to week 24/LOCF were ana-
lysed using an analysis of covariance (ANCOVA) model. For the per-
centage of patients with HbA1c <7.0% at week 24, data were
analysed using logistic regression,14,15 with adjustments for baseline
HbA1c. These analyses were performed using data from patients
who received at least 1 dose of double-blind study drug during the
randomized treatment period (randomized data set). Values prior to
initiation of rescue medication were used for analysis of these data.
The treated data set includes all patients who received at least 1 dose
of double-blind study drug during the treatment period, regardless of
rescue.
3 | RESULTS
3.1 | Patient disposition and baseline characteristics
Of the 1736 patients enroled, 794 (45.7%) were eligible to enter the
placebo lead-in period, of whom 568 patients were randomized (1:1)
to receive either once-daily metformin XR (N = 283) or twice-daily
metformin IR (N = 285) (Figure S1). The most common reason for
study non-eligibility or non-randomization was no longer meeting
study criteria (Figure S1). Of those patients who were randomized,
29 were excluded because of study site non-compliance. Thus, the
randomized data set became metformin XR (N = 268) and metformin
IR (N = 271). Overall, 245 patients in both groups completed the
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double-blind period of the study. Baseline demographics and disease
characteristics are shown in Table S1.
3.2 | Extent of exposure
Patients receiving once-daily metformin XR and twice-daily metfor-
min IR had similar exposure and total daily doses of study drug
(Table S2). Down-titration because of metformin intolerance was
implemented in 37 and 108 patients receiving metformin XR and IR,
respectively. However, for patients who were down-titrated, up-titra-
tions/rechallenges with higher doses were attempted before week
12. Eight patients received rescue medication (metformin XR, n = 3;
metformin IR, n = 5) (Table S2).
3.3 | Efficacy
Baseline mean (standard deviation) HbA1c was 7.58% (0.6) for met-
formin XR and 7.76% (0.5) for metformin IR. The adjusted mean
change (standard error [SE]) in HbA1c from baseline to week 24 was
similar between treatment arms (metformin XR, −0.93% [0.05]; met-
formin IR, −0.96% [0.05]), resulting in a non-significant difference of
0.03% between groups (95% confidence interval, −0.10 to 0.17)
(Figure 1). A subgroup analysis using baseline HbA1c supported this
finding (Table S3). Baseline adjusted changes in mean (SE) FPG and
MDG levels, and percentage of patients with HbA1c <7.0% at week
24/LOCF were similar between treatment arms (Table 1), as were
changes in body weight, waist circumference and serum lipid profiles
(Table S4).
3.4 | Safety and tolerability
Overall, 50.2% (142/283) and 47.4% (135/285) of patients in the
metformin XR and IR groups reported at least 1 treatment-emergent
AE, respectively (Table S5). Of these, 10.6% and 8.8% were consid-
ered treatment-related, respectively. Serious AEs (SAEs) were
reported for 2.8% (8/283) and 3.5% (10/285) of patients receiving
metformin XR and IR, respectively; only 1 case per group was consid-
ered treatment-related. The most common reason for discontinuation
because of AEs was GI disorders (metformin XR, 1.4%; metformin IR,
1.4%). The most frequently reported AEs were GI in nature, ie,
diarrhoea, nausea and vomiting (Table S5). There were no clinically
meaningful changes in vital signs or standard laboratory variables,
including creatinine, hepatic panel and urinalysis parameters.
3.5 | Hypoglycaemia
After 24 weeks of treatment, no hypoglycaemia events were
reported in patients receiving once-daily metformin XR compared
with 3 patients (1.1%) receiving twice-daily metformin IR. There were
5 events in total: 2 classified as “probable symptomatic hypoglycae-
mia” and 3 as “relative hypoglycaemia” (according to American Diabe-
tes Association recommendations).
4 | DISCUSSION
Few head-to-head trials have been conducted to establish therapeu-
tic equivalency of metformin IR and XR formulations.11,12 We report
an international, 24-week, head-to-head trial of metformin XR and IR
conducted in pharmacotherapy-naïve patients with type 2 diabetes.
The results demonstrate that once-daily metformin XR 2000 mg and
twice-daily metformin IR 1000 mg monotherapy have similar efficacy
and safety profiles.
The primary efficacy endpoint demonstrated the non-inferiority
of metformin XR compared with metformin IR, which was confirmed
in subgroup analysis by baseline HbA1c. Results from the 3 secondary
efficacy endpoints, change from baseline to week 24 in FPG and
MDG and proportion of patients achieving a therapeutic glycaemic
response of HbA1c <7.0% at week 24, supported this finding. In the
previously reported 24-week head-to-head study,12 the mean
decrease in HbA1c from baseline to week 24 for once-daily metfor-
min XR 2000 mg was −1.06%, similar to the value reported in this
study. Patients in the metformin IR group received a lower dose than
was used here (500 mg in the morning and 1000 mg in the evening
vs 1000 mg twice daily) and experienced a mean decrease in HbA1c
of −0.70%.
Once-daily metformin XR and twice-daily metformin IR were well
tolerated, as reported in the literature11,12 and product labelling.1
Notably, the most common AE was diarrhoea in both treatment
groups. The frequency of nausea was slightly higher with metformin
XR than with metformin IR (4.6% vs 2.8%, respectively), which
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FIGURE 1 Adjusteda mean change (SE) in
HbA1c (%) from baseline to week 24 for
patients receiving twice-daily metformin IR
or once-daily metformin XR (randomized
data set)b. aAdjusted for baseline HbA1c,
treatment group, time, baseline-by-time
interaction and time-by-treatment group
interaction and bexcluding data after
rescue medication. Abbreviations: HbA1c,
glycated haemoglobin; IR, immediate
release; SE, standard error; XR, extended
release
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contrasts with the previous head-to-head trials11,12; however, overall,
nausea was reported by few patients in both groups. Moreover, AEs
and SAEs leading to study discontinuation were reported for fewer
than 5% of patients in both treatment groups.
In this study, down-titration because of metformin intolerance1
was necessary in almost 3 times as many patients treated with met-
formin IR compared with metformin XR. The reduced requirement
for down-titration from 2000 mg/d with metformin XR, in addition
to the once-daily dosing regimen, may help to improve the patient
and physician experience. Patients in this study were highly selected
(a large proportion of patients did not meet the study criteria) and
were motivated to comply with medication; however, outside of a
controlled study setting, the potential patient compliance benefits of
once-daily vs twice-daily dosing are more likely to become
apparent.
In conclusion, this international head-to-head trial has demon-
strated the therapeutic equivalence of metformin XR and metformin
IR over a 24-week period in pharmacotherapy-naïve patients with
type 2 diabetes, and confirms metformin XR as an important treat-
ment option for patients in whom dosing frequency could affect
medication compliance and compromise treatment outcomes.
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TABLE 1 Adjusted mean changes in secondary efficacy endpoints from baseline to week 24 (randomized data set)a
Secondary efficacy endpoint
Metformin XR
2000 mg QD
(N = 268)
Metformin IR
1000 mg BID
(N = 271)
Difference
(95% CI)
FPG, mg/dL
Baseline, mean (SD) 153.8 (30.7) 157.9 (33.0) –
Week 24, mean (SD) 131.9 (31.2) 134.9 (27.9) –
Adj mean change from baseline (SE)b n = 228 n = 229
−21.1 (1.8) −20.6 (1.8) −0.5 (−5.5 to 4.5)
MDG, mg/dL
Baseline, mean (SD) 161.4 (29.8) 169.9 (31.5) –
Week 24 (LOCF), mean (SD) 139.3 (26.2) 140.4 (26.0) –
Adj mean change from baseline (SE)c n = 211 n = 218
−24.7 (1.6) −27.1 (1.6) 2.4 (−2.0 to 6.8)
Patients achieving HbA1c <7.0%
Week 24, patients (%) n = 237 n = 237
174 (73.4) 166 (70.0) –
Week 24, adjusted % (SE) 70.9 (2.8) 72.0 (2.9) −1.1 (−8.7 to 6.5)
Abbreviations: Adj, adjusted; BID, twice daily; CI, confidence interval; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; IR, immediate release;
LOCF, last observation carried forward; MDG, mean daily glucose; QD, once daily; SD, standard deviation; SE, standard error; XR, extended release.
n values are number of randomized patients who had non-missing baseline values and values at week 24.
Data are adjusted mean changes from baseline, except for the responder rate (reported as percentage of patients achieving HbA1c <7.0% at week 24;
percentage adjusted for baseline HbA1c).
a Excluding data after rescue medication.
b Metformin XR vs metformin IR, −1.2 vs −1.1 mmol/L.
c Metformin XR vs metformin IR, −1.4 vs −1.5 mmol/L.
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